Jolanda M Maaskant

Dr. Jolanda M Maaskant


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in International Journal of Nursing Studies
Verified
Journal Article
Open access
JMJolanda M Maaskant
Jolanda M Maaskant
IJI.P. Jongerden
I.P. Jongerden
JBJ. Bik
J. Bik
MJM. Joosten
M. Joosten
SMS. Musters
S. Musters
AEA.M. Eskes
A.M. Eskes
The outbreak of the COVID-19 pandemic influenced family-centred care dramatically due to restricting visiting policies. In this new situation, nurses were challenged to develop new approaches to involve family members in patient care. A better understanding of these changes and the experiences of nurses is essential to make an adaptation of procedures, and to secure a family-centred approach in care as much as possible. The aim of this study was to investigate how family involvement had taken place, and to explore the experiences of nurses with family involvement during the COVID-19 outbreak. In addition, we aimed to formulate recommendations for the involvement of family. We conducted a qualitative study using patient record review and focus-group interviews between April and July 2020. We reviewed records of patients with confirmed COVID-19, who were admitted to the COVID-19 wards at two affiliated university hospitals in the Netherlands. All records were searched for notations referring to family involvement. In two focus-groups, nurses who worked at the COVID-19 wards were invited to share their experiences. The Rigorous and Accelerated Data Reduction (RADaR) method was used to collect, reduce and analyse the data. In total, 189 patient records were reviewed and nine nurses participated in the focus-group meetings. Patient records revealed infrequent and often unstructured communication with focus on physical condition. Nurses confirmed that communication with family was far less than before and that the physical condition of the patient was predominant. The involvement of family in care was limited to practicalities, although more involvement was described in end-of-life situations. Nurses experienced moral distress due to the visiting restrictions, though some acknowledged that they had experienced the direct patient care so intense and burdensome, that family contact simply felt too much. The communication with and involvement of family in hospital care changed enormously during the COVID-19 outbreak. Based on the identified themes, we formulated recommendations that may be helpful for family-centered care in hospitals during periods of restricted visiting policy.

10 May 2016 in European journal of pain
Verified
Journal Article
Closed access
PDF file
JMJolanda M Maaskant
Jolanda M Maaskant
PRP. Raymakers‐Janssen
P. Raymakers‐Janssen
EVE. Veldhoen
E. Veldhoen
EIE. Ista
E. Ista
CLC. Lucas
C. Lucas
HVHester Vermeulen
Hester Vermeulen

2 August 2013 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
JMJolanda M Maaskant
Jolanda M Maaskant
AEAnne Eskes
Anne Eskes
PRPetra van Rijn-Bikker
Petra van Rijn-Bikker
DBDiederik Bosman
Diederik Bosman
WAWim van Aalderen
Wim van Aalderen
HVHester Vermeulen
Hester Vermeulen
The available knowledge about high-alert medications for children is limited. Because children are particularly vulnerable to medication errors, a list of high-alert medication specifically for children would help to develop effective strategies to prevent patient harm. Therefore, we conducted an international modified Delphi study and validated the results with reports on medication incidents in children based on national data. The objective of this study was to generate an internationally accepted list of high-alert medications for a pediatric inpatient population from birth to 18-years old. The rating panel consisted of 34 experts from 13 countries. In total, 14 medications and 4 medication classes were included with the predefined level of consensus of 75%. The high-alert medications were: amiodarone, digoxin, dopamine, epinephrine, fentanyl, gentamycin, heparine, insulin, morphine, norepinephrine, phenytoin, potassium, propofol and tacrolimus. The high-alert medication classes included in the final list were: chemotherapeutic drugs, immunosuppressive medications, lipid/total parenteral nutrition and opioids. An international group of experts defined 14 medications and 4 medication classes as high-alert for children. This list might be helpful as a starting point for individual hospitals to develop their own high-alert list tailored to their unique situation.

1 April 2013 in Journal of Pediatric Nursing
Verified
Journal Article
Closed access
JMJolanda M Maaskant
Jolanda M Maaskant
AKAnouk M. Knops
Anouk M. Knops
DUDirk T. Ubbink
Dirk T. Ubbink
HVHester Vermeulen
Hester Vermeulen

2 June 2017 in European journal of pain
Verified
Journal Article
Open access
PDF file
PVP. Vink
P. Vink
CLC. Lucas
C. Lucas
JMJolanda M Maaskant
Jolanda M Maaskant
WEW.S. van Erp
W.S. van Erp
RLRobert Lindeboom
Robert Lindeboom
HVHester Vermeulen
Hester Vermeulen
The Nociception Coma Scale is a nociception behaviour observation tool, developed specifically for patients with disorders of consciousness (DOC) due to (acquired) brain injury. Over the years, the clinimetric properties of the NCS and its revised version (NCS‐R) have been assessed, but no formal summary of these properties has been made. Therefore, we performed a systematic review on the clinimetric properties (i.e. reliability, validity, responsiveness and interpretability) of the NCS(‐R). We systematically searched CENTRAL, CINAHL, Embase, PsycInfo and Web of Science until August 2015. Two reviewers independently selected the clinimetric studies and extracted data with a structured form. Included studies were appraised on quality with the COSMIN checklist. Eight studies were found eligible and were appraised with the COSMIN checklist. Although nearly all studies lacked sample size calculation, and were executed by the same group of authors, the methodological quality ranged from fair to excellent. Important aspects of reliability, construct validity and responsiveness have been studied in depth and with sufficient methodological quality. The overview of clinimetric properties in this study shows that the NCS and NCS‐R are both valid and useful instruments to assess nociceptive behaviour in DOC patients. The studies provide guidance for the choice in NCS‐R cut‐off value for possible pain treatment and cautions awareness of interprofessional differences in NCS‐R measurements.Significance: This systematic review provides a structured overview of the clinimetric properties of the Nociception Coma Scale (‐Revised) and provides insights for a solid evidence‐based nociception behaviour assessment and treatment plan.

19 January 2018 in Health Science Reports
Verified
Journal Article
Open access
PDF file
JMJolanda M Maaskant
Jolanda M Maaskant
MTMarieke A. Tio
Marieke A. Tio
RHReinier M. Van Hest
Reinier M. Van Hest
HVHester Vermeulen
Hester Vermeulen
VGVincent G.M. Geukers
Vincent G.M. Geukers
Objective: Medication errors (MEs) are one of the most frequently occurring types of adverse events in hospitalized patients and potentially more harmful in children than in adults. To increase medication safety, we studied the effect of structured medication audit and feedback by a clinical pharmacist as part of the multidisciplinary team, on MEs in critically ill children.Method: We performed an interrupted time series analysis with 6 preintervention and 6 postintervention data collection points, in a tertiary pediatric intensive care unit. We included intensive care patients admitted during July to December 2013 (preintervention) and July to December 2014 (postintervention). The primary endpoint was the prevalence of MEs per 100 prescriptions. We reviewed the clinical records of the patients and the incident reporting system for MEs. If an ME was suspected, a pediatrician‐intensivist and a clinical pharmacist determined causality and preventability. They classified MEs as harmful according to the National Coordinating Council for Medication Error Reporting and Prevention categories.Results: We included 254 patients in the preintervention period and 230 patients in the postintervention period. We identified 153 MEs in the preintervention period, corresponding with 2.27 per 100 prescriptions, and 90 MEs in the postintervention period, corresponding with 1.71 per 100 prescriptions. Autoregressive integrated moving average analyses revealed a significant change in slopes between the preintervention and postintervention periods (β = −.21; 95% CI, −0.41 to −0.02; P = .04). We did not observe a significant decrease immediately after the start of the intervention (β = −.61; 95% CI, −1.31 to 0.08; P = .07).Conclusion: The implementation of a structured medication audit, followed by feedback by a clinical pharmacist as part of the multidisciplinary team, resulted in a significant reduction of MEs in a tertiary pediatric intensive care unit.